United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

12:03pm EST
Change (% chg)

$0.46 (+0.39%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for CELG.O


Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology... (more)


Beta: 1.78
Market Cap(Mil.): $96,249.27
Shares Outstanding(Mil.): 775.20
Dividend: --
Yield (%): --


  CELG.O Industry Sector
P/E (TTM): 47.06 42.21 29.87
EPS (TTM): 2.64 -- --
ROI: 8.82 -1.09 14.95
ROE: 38.66 -2.39 16.29

Bluebird, Celgene myeloma treatment impresses in tiny study

Patients who previously were not helped by repeated treatments for multiple myeloma showed strong benefits from a new type of therapy in a small study, and with no worrisome side effects, drugmaker Bluebird Bio Inc said on Wednesday.

Nov 30 2016

BRIEF-Celgene enters into service and license arrangement for GNS Healthcare's causal machine learning platform

* Celgene enters service,license arrangement for rights to operate GNS Healthcare REFS(TM) causal machine learning and simulation platform

Nov 29 2016

BRIEF-MaRS Innovation announces acquisition of first compound from Triphase by Celgene

* Triphase accelerator to sell assets relating to Marizomib to Celgene, via affiliate, for undisclosed amount

Nov 21 2016

BRIEF-PharmAkea extends collaboration with Celgene

* Pharmakea Inc-extension of strategic collaboration with Celgene for its drug discovery platform and novel small-molecule therapies targeting fibrotic diseases Source text for Eikon:

Nov 18 2016

BRIEF-Triphase Accelerator says Celgene will buy co's assets related to marizomib

* says Celgene Corp, through an affiliate, has acquired co's assets related to its proteasome inhibitor, marizomib

Nov 17 2016

BRIEF-Celgene - Data on early onset of efficacy for oral otezla in active psoriatic arthritis presented at American College Of Rheumatology

* Celgene Corp - active trial in biologic-naïve patients met its primary endpoint

Nov 14 2016

BRIEF-Celgene and IBM Watson Health collaborate to transform patient safety monitoring

* Celgene and IBM Watson Health forge collaboration designed to transform patient safety monitoring

Nov 01 2016

BRIEF-Celgene Corp reports 12.3 pct stake in CRISPR Therapeutics AG - SEC filing

* Celgene Corp reports 12.3 percent stake in CRISPR Therapeutics Ag as of October 24 - SEC filing Source text for Eikon: Further company coverage: ;))

Oct 31 2016

Fund manager wins challenge to Celgene drug safety patents

A U.S. Patent and Trademark Office tribunal has invalidated two Celgene Corp patents related to its cancer drugs Revlimid, Pomalyst and Thalomid, marking a second victory for hedge fund manager Kyle Bass in his ongoing campaign of challenging drug patents.

Oct 28 2016

BRIEF-Celgene files for potential mixed shelf offering

* Files for potential mixed shelf; size not disclosed - sec filing Source: http://bit.ly/2eg2oOZ Further company coverage:

Oct 27 2016


  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥4,645 +23.00
Eisai Co., Ltd (4523.T) ¥6,440 -45.00
Johnson & Johnson (JNJ.N) $112.07 +0.13
Novartis AG (NOVN.S) CHF69.35 -0.15
Pfizer Inc. (PFE.N) $31.46 -0.13
Roche Holding Ltd. (ROG.S) CHF222.30 +0.20
Roche Holding Ltd. (RO.S) CHF226.30 +0.30
Merck & Co., Inc. (MRK.N) $59.88 -0.37
Sanofi SA (SASY.PA) €75.55 -0.51
AstraZeneca plc (AZN.L) 4,037.50p +4.00

Earnings vs. Estimates